Many cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedited (“fast track”) pathways, finds a study published by The BMJ today.
New method provides valuable insights into the brain’s noradrenaline system
An international team of researchers has provided valuable insights into the brain’s noradrenaline (NA) system, which has been a longtime target for medications to treat
October 24, 2023